Clinical Trials
Like many of our faculty members, Rabi Yacoub, MD, is involved in running clinical trials. An expert on the effects of gut microbiota dysbiosis on renal diseases, he has participated in trials evaluating the diversities and population of gut bacteria in patients with different degrees of renal insufficiencies.
We are dedicated to studying potential new treatments and offering patients the latest diagnostic and care options before they’re widely available.
Our physician-scientists design and run clinical trials backed by a variety of funding sources, and our fellows are involved in conducting the research, gaining the professional experience they need to lead future trials.
Members of our division have been responsible for clinical trials that have led to groundbreaking therapies for transplant recipients. Through our efforts in multicenter and investigator-initiated efforts, we stay abreast of the newest developments in immunological research and drug development, providing our patients access to these ever-evolving advances.
Western New York has a large patient population afflicted with polycystic kidney disease, and through clinical trials, our division works toward establishing potential new treatment paradigms for these patients.
Our division also conducts clinical trials studying the safety and efficacy of various drugs in kidney diseases, and we participate in clinical trials related to:
- treatment of anemia in chronic kidney disease and hypertension
- dialysis
- treatment of diabetic kidney disease
We have a firm commitment to promoting the highest quality of care our discipline can offer for people in Western New York and around the world. Pursuing innovative approaches through clinical trials forms a key component of this mission. The UB Institutional Review Board reviews and monitors all of our research to ensure subjects are treated with the utmost respect and dignity throughout the course of each study.